REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Dec 18, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-12-14

Reporting Person: STAHL NEIL (SVP Res and Devel Sciences)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-12-14	Common Stock	F	8386.0	$179.13	Disposed	43036.0	Direct
2012-12-17	Common Stock	M	5952.0	$16.8	Acquired	48988.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-17	Incentive Stock Option (right to buy)	$16.8	M	5952.0	Disposed	2018-12-17	Common Stock (5952.0)	Direct
2012-12-14	Non-Qualified Stock Option (right to buy)	$21.25	A	75000.0	Acquired	2019-12-18	Common Stock (75000.0)	Direct
2012-12-14	Non-Qualified Stock Option (right to buy)	$179.13	A	112500.0	Acquired	2022-12-14	Common Stock (112500.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5479.0	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F3: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

F4: On December 18, 2009, the reporting person was granted an option to purchase 75,000 shares of Common Stock. The option vests, partially or in full, on December 31, 2012, based on the extent to which the company satisfies certain performance criteria during the period ending December 31, 2012. The performance criteria have been met and the option will vest as to all 75,000 shares on December 31, 2012.

F5: The stock option award vests in four equal annual installments, commencing one year after the date of grant.